Thermo Fisher Scientific (NYSE:TMO) Shares Gap Down - Time to Sell?

Key Points

• Thermo Fisher reported strong third-quarter results: Revenue rose 9% year over year to $12.14 billion, while adjusted EPS increased 15% to $6.68, beating analyst estimates. Improved margins and 6% organic growth indicated resilient demand and operating leverage.
• Shares initially fell despite the earnings beat, opening at $665 versus a prior close of $687.37. The decline may reflect elevated expectations and concerns about the stock’s premium valuation, while above-average put-option activity signals increased near-term hedging or bearish speculation.
• Analyst sentiment remains broadly positive, with a “Moderate Buy” consensus and recent price-target increases from TD Cowen and Morgan Stanley. However, insiders have sold more than 73,000 shares worth approximately $44.1 million over the past three months.

Thermo Fisher Scientific Inc. (NYSE:TMO - Get Free Report)'s share price gapped down before the market opened on Wednesday. The stock had previously closed at $687.37, but opened at $665.00. Thermo Fisher Scientific shares last traded at $690.1890, with a volume of 732,999 shares traded.

Key Stories Impacting Thermo Fisher Scientific

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: Thermo Fisher reported third-quarter revenue of $12.14 billion, up 9% year over year and above the approximately $11.95 billion consensus estimate. Adjusted EPS rose 15% to $6.68, beating expectations of $6.40, while organic revenue growth reached 6%. Thermo Fisher Scientific Reports Third Quarter 2026 Results
• Positive Sentiment: Improved margins and double-digit adjusted profit growth suggest operating leverage and resilient demand across the company’s life-science tools and services businesses. The quarter also extended Thermo Fisher’s record of earnings beats. Thermo Fisher posts higher third-quarter revenue and earnings as margins improve
• Neutral Sentiment: The broader bioprocessing market is expected to expand as biologics manufacturing, vaccine production, outsourcing, artificial intelligence and single-use systems gain adoption. This provides a favorable industry backdrop for Thermo Fisher, though the market reports are not company-specific financial guidance. Global Bioprocessing Reagent Market Report 2026
• Negative Sentiment: Despite the earnings and revenue beats, shares initially fell in premarket trading. The decline likely reflected high investor expectations following a strong run-up, as well as potential concerns about whether the results and outlook were strong enough to justify TMO’s premium valuation. TMO Q3 Earnings and Revenues Beat Estimates
• Negative Sentiment: Investors purchased 4,906 put options, 52% above typical put volume of 3,229 contracts. The activity signals increased near-term hedging or bearish speculation, although options flow alone does not establish a longer-term negative outlook.

Analyst Ratings Changes

Several analysts recently weighed in on the stock. Weiss Ratings raised shares of Thermo Fisher Scientific from a "hold (c+)" rating to a "buy (b-)" rating in a report on Thursday, October 8th. CLSA began coverage on shares of Thermo Fisher Scientific in a report on Thursday, September 3rd. They set an "outperform" rating and a C$748.00 price target for the company. Sanford C. Bernstein initiated coverage on shares of Thermo Fisher Scientific in a research report on Friday, June 26th. They issued a "market perform" rating and a $520.00 price objective on the stock. TD Cowen raised their price objective on shares of Thermo Fisher Scientific from $675.00 to $760.00 and gave the company a "buy" rating in a report on Tuesday, October 13th. Finally, Morgan Stanley lifted their price objective on shares of Thermo Fisher Scientific from $650.00 to $730.00 and gave the stock an "overweight" rating in a research report on Monday, October 12th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, three have given a Hold rating and two have issued a Sell rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $654.05.

Thermo Fisher Scientific Stock Performance

The firm has a 50 day moving average of $640.60 and a two-hundred day moving average of $551.25. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.55 and a quick ratio of 1.18. The stock has a market cap of $259.64 billion, a PE ratio of 37.74, a PEG ratio of 2.83 and a beta of 0.87.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings results on Wednesday, October 21st. The medical research company reported $6.68 EPS for the quarter, beating the consensus estimate of $6.40 by $0.28. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The company had revenue of $12.14 billion for the quarter, compared to analyst estimates of $11.95 billion. During the same period in the prior year, the firm posted $5.79 earnings per share. The firm's revenue was up 9.1% on a year-over-year basis. Research analysts predict that Thermo Fisher Scientific Inc. will post 25.13 EPS for the current fiscal year.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, VP Lisa P. Britt sold 11,440 shares of the company's stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $613.12, for a total value of $7,014,092.80. Following the completion of the transaction, the vice president owned 14,784 shares in the company, valued at $9,064,366.08. This represents a 43.62% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CAO Joseph R. Holmes sold 420 shares of the firm's stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $584.81, for a total value of $245,620.20. Following the transaction, the chief accounting officer directly owned 2,966 shares in the company, valued at approximately $1,734,546.46. The trade was a 12.40% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 73,768 shares of company stock worth $44,122,820. Insiders own 0.33% of the company's stock.

Institutional Trading of Thermo Fisher Scientific

Several institutional investors and hedge funds have recently made changes to their positions in TMO. Bell Bank boosted its holdings in shares of Thermo Fisher Scientific by 10.8% in the 3rd quarter. Bell Bank now owns 624 shares of the medical research company's stock valued at $421,000 after purchasing an additional 61 shares during the last quarter. 55 North Private Wealth LLC grew its stake in shares of Thermo Fisher Scientific by 40.9% during the 3rd quarter. 55 North Private Wealth LLC now owns 906 shares of the medical research company's stock valued at $612,000 after buying an additional 263 shares during the period. Jeppson Wealth Management LLC acquired a new stake in shares of Thermo Fisher Scientific during the 3rd quarter worth $213,000. James Hambro & Partners LLP increased its holdings in shares of Thermo Fisher Scientific by 0.8% during the 3rd quarter. James Hambro & Partners LLP now owns 231,390 shares of the medical research company's stock worth $156,260,000 after buying an additional 1,919 shares during the last quarter. Finally, James T. Borello RIA purchased a new position in shares of Thermo Fisher Scientific in the 3rd quarter worth $57,000. 89.23% of the stock is owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc is a global supplier of laboratory products, analytical instruments, reagents, consumables, software and services used in scientific research, healthcare, pharmaceuticals, biotechnology and industrial applications. The company serves customers ranging from academic institutions and government agencies to hospitals, clinical laboratories and pharmaceutical manufacturers.

Its offerings include instruments and systems for genetic analysis, mass spectrometry, chromatography, electron microscopy and materials science, as well as molecular biology reagents, cell culture products, laboratory plastics and research chemicals.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.